Abionic SA is a company specialized in the development of ultra-rapid in vitro diagnostic tests, located in Lausanne, Switzerland.

The abioSCOPE is implemented in intensive care units and emergency departments to enable early identification of sepsis using a proprietary biomarker, Pancreatic Stone Protein (PSP).

Secreted mainly by the pancreas and stomach, PSP rises rapidly in the blood in case of sepsis development and up to 72 hours before today's standard of care.

Abionic's solution is composed of the abioSCOPE, an in vitro diagnostic device and the consumable called the IVD CAPSULE, which is a single-use and analyte-specific tests.

The volume-to-surface ratio then forces the molecules to interact immediately together, limiting their travel distance and reducing the incubation time to a few minutes.